Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based biotechnology company, on Thursday announced final data from the Phase one clinical trial of its investigational breast cancer vaccine (NCT04674306) at the 2025 San Antonio Breast Cancer Symposium (SABCS).

The trial was carried out in partnership with Cleveland Clinic and funded by a grant from the US Department of Defence.

Final Phase one results revealed that the investigational vaccine met all major primary endpoints. It was safe and well tolerated at the maximum tolerated dose (MTD), and elicited protocol-defined immune responses in 74% of participants.

Topline Phase one results indicated that all major primary endpoints were met. It assessed safety and monitored immune response to an investigational vaccine targeting alpha-lactalbumin (aLA).